Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Regulatory News (VER)

  • There is currently no data for VER

Annual Information Update

7 Aug 2007 14:03

Vernalis PLC07 August 2007 VERNALIS PLC ANNUAL INFORMATION UPDATE As required under Prospectus Rule 5.2, and following publication of the AnnualReport on 20th April 2007, the following summarises the information anddocuments published or made available to the public by the Company between 24thMay 2006 and 6th August 2007 inclusive. This Annual Information Update is also being made available on the Investorssection of the Company's website at www.vernalis.com. The information referred to in this Annual Information Update was correct at thetime it was published but some information may now be out of date. 1. Announcements made via a Regulatory Information Service ("RIS") Date Description of Contents of Announcement24/05/2006 Results of the AGM19/06/2006 Investor Conferences05/07/2006 Holding(s) in Company20/07/2006 sNDA for Frova28/07/2006 Additional Listing03/08/2006 Phase IIa Trial of V338103/08/2006 Holding(s) in Company23/08/2006 Notice of Results12/09/2006 Interim Results - Part 112/09/2006 Interim Results - Part 213/09/2006 Director/PDMR Shareholding20/09/2006 Filing of Frova(R)20/09/2006 UBS Global Life Sciences Conf02/11/2006 Global Health Care Conference20/11/2006 Oncology Hsp90 Programme21/11/2006 Piper Jaffray Healthcare Conf11/12/2006 Phase I Trial of V2434320/12/2006 Appointment of Ian Clark20/12/2006 Total Voting Rights29/01/2007 Notice of Results29/01/2007 Holding(s) in Company12/03/2007 Preliminary Results - Part 112/03/2007 Preliminary Results - Part 212/03/2007 Preliminary Results - Part 312/03/2007 Frova(R) in France16/03/2007 PDUFA date for Frova(R) sNDA22/03/2007 Holding(s) in Company20/04/2007 Holding(s) in Company24/04/2007 Nasdaq Stock Market08/05/2007 Biogen Idec and Vernalis17/05/2007 Drug Discovery Collaboration23/05/2007 AGM Statement04/06/2007 Director's Share Dealing06/06/2007 Director/PDMR Shareholding11/06/2007 Frova Phase III Data16/07/2007 Phase IIa Trial of V338102/08/2007 Holdings(s) in Company All of the above UK regulatory announcements have been made via a RIS and can beobtained from the London Stock Exchange's website at www.londonstockexchange.comor the Company's website at www.vernalis.com. 2. Documents filed at Companies House All the documents listed below were filed with the Registrar of Companies inEngland and Wales on or around the dates indicated. Date Document Type31/05/2006 Annual Report and Accounts31/05/2006 Memorandum and Articles of Association03/06/2006 Annual General Meeting Resolutions04/08/2006 Form 88(2) - Return of Allotment of Shares05/08/2006 Form 288b - Resignation of Director18/08/2006 Form 363s - Annual Return17/01/2007 Form 288a - Appointment of Director25/05/2007 Annual Report and Accounts30/05/2007 Annual General Meeting Resolutions Copies of the above documents, filed with the Registrar of Companies, can beobtained from the Companies House website at www.companieshouse.gov.uk, or canbe obtained from Companies House, Crown Way, Cardiff, CF14 3UZ. 3. Documents published or sent to Shareholders or filed with the UK ListingAuthority or submitted to the FSA All the documents below were submitted to the FSA/UKLA on or around the datesindicated. Date Document20/07/2006 Application for Admission of Securities to the Official List20/07/2006 Form 1 - Application for Admission of Securities to Trading12/09/2006 Interim Report12/03/2007 Preliminary Report20/04/2007 Annual Report and Circular/Notice of Meeting Certain documents submitted to the FSA can be viewed at the Document ViewingFacility situated at The Financial Services Authority, 25 The North Colonnade,Canary Wharf, London, E14 5HS. The Notice of Annual General Meeting and Annual, Interim and Preliminary Reportsare also available via the Investors section of the Company's website atwww.vernalis.com. 4. Documents lodged with the Securities and Exchange Commission The documents listed below were filed with the SEC on or around the datesindicated. Date Document11/05/2006 Form 6-K - Report of foreign issuer (Rules 13a-16 and 15d-16)29/06/2006 20-F Annual and transition report of foreign private issuers (Sections 13 or 15(d))13/07/2006 Form 6-K - Report of foreign issuer (Rules 13a-16 and 15d-16)21/08/2006 Form 6-K - Report of foreign issuer (Rules 13a-16 and 15d-16)05/09/2006 Form 6-K - Report of foreign issuer (Rules 13a-16 and 15d-16)29/09/2006 Correspondence02/10/2006 Form 6-K - Report of foreign issuer (Rules 13a-16 and 15d-16)27/10/2006 SEC Generated Letter16/11/2006 SEC Generated Letter30/11/2006 Correspondence08/12/2006 SEC Generated Letter11/12/2006 Form 6-K - Report of foreign issuer (Rules 13a-16 and 15d-16)08/01/2007 Form 6-K - Report of foreign issuer (Rules 13a-16 and 15d-16)07/02/2007 Form 6-K - Report of foreign issuer (Rules 13a-16 and 15d-16)16/02/2007 Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals04/04/2007 Form 6-K - Report of foreign issuer (Rules 13a-16 and 15d-16)24/04/2007 Form 6-K - Report of foreign issuer (Rules 13a-16 and 15d-16)04/05/2007 Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities04/06/2007 Form 6-K - Report of foreign issuer (Rules 13a-16 and 15d-16)04/06/2007 Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments04/06/2007 Form 15F-12G - Securities registration termination of foreign private issuers (Section 12(g))04/06/2007 Form F-6 POS - Post-effective amendments for immediately effective filing Copies of the above documents are available for viewing on the Securities andExchange Commission website at www.sec.gov. 5. Further Information Further information about Vernalis plc can be found on our website atwww.vernalis.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
25th Nov 201410:13 amRNSHolding(s) in Company
18th Nov 20147:00 amRNSChange of Year End & Commercial Business Update
6th Nov 20147:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
5th Nov 201412:15 pmRNSHolding(s) in Company
5th Nov 201412:07 pmRNSHolding(s) in Company
3rd Nov 20145:06 pmRNSHolding(s) in Company
31st Oct 20145:17 pmRNSHolding(s) in Company
31st Oct 20147:00 amRNSTotal Voting Rights
27th Oct 20147:00 amRNSCTI becomes worldwide licensee for tosedostat
14th Oct 20143:55 pmRNSTransactions of Directors
10th Oct 20147:00 amRNSVernalis opens US office and strengthens US team
9th Oct 20147:00 amRNSVernalis licenses V2006 to RedoxTherapies Inc
15th Sep 20147:00 amRNSFDA accepts TuzistraTM XR NDA for full review
5th Sep 201410:30 amRNSHolding(s) in Company
29th Aug 20144:00 pmRNSTotal Voting Rights
14th Aug 201410:59 amRNSHolding(s) in Company
5th Aug 20147:00 amRNSInterim results for six months ended 30 June 2014
4th Aug 20147:00 amRNSVernalis & Servier achieve 2 Research Milestones
31st Jul 20147:00 amRNSTotal Voting Rights
22nd Jul 20147:00 amRNS3rd Product in Cough Cold Pipeline Achieves POC
17th Jul 20147:00 amRNSNotice of Results for 6 Months Ended 30 June 2014
30th Jun 20147:15 amRNSTotal Voting Rights
30th Jun 20147:00 amRNSSubmission of TuzistraTM XR (CCP-01) NDA to FDA
19th Jun 20147:00 amRNSVernalis & Servier Achieve Research Milestone
30th May 20143:30 pmRNSTotal Voting Rights
23rd May 201411:48 amRNSResult of AGM
16th May 201410:47 amRNSHolding(s) in Company
6th May 20146:16 pmRNSBLOCK LISTING SIX MONTHLY RETURN
6th May 20144:31 pmRNSHolding(s) in Company
1st May 20143:15 pmRNSHolding(s) in Company
30th Apr 20149:00 amRNSTotal Voting Rights
29th Apr 20147:00 amRNS2nd Product in Cough Cold Pipeline Achieves POC
24th Apr 20147:00 amRNSPromising Results of Ph Ib/II POC Study in ADHD
22nd Apr 20147:01 amRNSVernalis Research wins Queens Award for Enterprise
15th Apr 20147:00 amRNSNotice of Annual Report and AGM
7th Apr 20145:41 pmRNSTransactions of Directors and Applicable Employee
1st Apr 20147:00 amRNSAnnouncement of Results for year ended 31 Dec 2013
31st Mar 20144:23 pmRNSTotal Voting Rights
27th Mar 20147:00 amRNSVernalis and Asahi Kasei Pharma Achieve Milestone
6th Mar 20147:00 amRNSAppointment of Joint Broker
5th Mar 20143:00 pmRNSNotice of Results
24th Feb 20147:00 amRNSVernalis Announces Successful Completion of Study
7th Feb 20147:00 amRNSAppointment of Nominated Adviser and Broker
29th Nov 20137:00 amRNSTotal Voting Rights
25th Nov 20137:00 amRNSVernalis Announces Successful Study with CCP-01
21st Nov 20135:05 pmRNSHolding(s) in Company
6th Nov 20137:00 amRNSBlock Listing Application
1st Oct 20134:40 pmRNSSecond Price Monitoring Extn
1st Oct 20134:35 pmRNSPrice Monitoring Extension
1st Oct 20137:00 amRNSVernalis enters into research collaboration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.